Immunotherapy combo aims to stop stomach cancer relapse
NCT ID NCT07492615
First seen Apr 14, 2026 · Last updated May 24, 2026 · Updated 4 times
Summary
This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It includes 276 adults with high-risk or certain genetic subtypes of stage III cancer. Participants are randomly assigned to receive either the combination or chemotherapy alone for up to 8 cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200230, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.